BGM Group Ltd. BGM

Full chart Compare
Set alert

Price alert · BGM

All alert types
8.41 USD -0.44 (-4.97%)

Nov 3, 2026, 1:53 PM EST

9.48 Day range 9.80
7.20 52-week range 296.55
YTD
-92.40%
1 year
-97.09%
Market cap
127.40M
Revenue (ttm)
29.87M
Profit margin
-26.32%
EPS (ttm)
-4.80
Shares out
180.62M
YTD return
-92.40%
1-year return
-97.09%
Volume
423
Avg volume
8.00K
Open
9.80
Previous close
8.85
Day's range
9.48 – 9.80
52-week range
7.20 – 296.55
Beta
1.46

1m +0.40 (+4.73%)

7.5088.509Nov 28.85

Key statistics

Enterprise value
69.18M
PEG ratio
0.00
Price / sales
30.29
Price / book
2.43
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-56.90%
Free cash flow
3.36M
Total cash
25.36M
Total debt
100.76K
Return on equity
-16.52%
Short % of float
0.43%
50-day average
8.33
200-day average
9.90

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
BGM Revenue — annual 37.92M
2018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
BGM Net income — annual -19.94M
2018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
BGM EPS — annual -5.40
2018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025

About BGM Group Ltd.

BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
China
Website
bgm.ltd

News

Your note

Sign in to keep a note on BGM — it syncs with the Stock Master app.

Institution ownership

BGM institution ownership
Holder% heldSharesValueReported
Invesco Ltd.0.46%162,885734.61KSep 29, 2025
Geode Capital Management, LLC0.13%45,251204.08KSep 29, 2025
State Street Corporation0.13%46,900211.52KSep 29, 2025
Mariner, LLC0.07%26,112117.77KSep 29, 2025
UBS Group AG0.02%7,34333.12KSep 29, 2025

Fund ownership

BGM fund ownership
Holder% heldSharesValueReported
Invesco Exchange-Traded Fund Trust-Invesco Golden Dragon China ETF0.45%162,084731.00KOct 30, 2025
SPDR INDEX SHARES FUNDS-SPDR(R) S&P(R) EMERGING MARKETS SMALL CAP ETF0.12%42,100189.87KSep 29, 2025
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund0.07%25,569115.32KOct 30, 2025
Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF0.06%19,72788.97KOct 30, 2025
SPDR INDEX SHARES FUNDS-SPDR(R) S&P(R) CHINA ETF0.01%4,80021.65KOct 30, 2025